<?xml version='1.0' encoding='utf-8'?>
<document id="17409861"><sentence text="Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer."><entity charOffset="68-78" id="DDI-PubMed.17409861.s1.e0" text="irinotecan" /><entity charOffset="83-93" id="DDI-PubMed.17409861.s1.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.17409861.s1.e0" e2="DDI-PubMed.17409861.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17409861.s1.e0" e2="DDI-PubMed.17409861.s1.e1" /></sentence><sentence text="The purpose of this study was to investigate the maximum tolerated doses, dose-limiting toxicities, efficacy, and pharmacokinetic profiles in the combination of irinotecan and paclitaxel"><entity charOffset="161-171" id="DDI-PubMed.17409861.s2.e0" text="irinotecan" /><entity charOffset="176-186" id="DDI-PubMed.17409861.s2.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.17409861.s2.e0" e2="DDI-PubMed.17409861.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17409861.s2.e0" e2="DDI-PubMed.17409861.s2.e1" /></sentence><sentence text=" Eligibility criteria included age 75 years or younger, good performance status, adequate organ function, and unresectable non-small cell or extensive disease of small cell lung cancer" /><sentence text=" Irinotecan was administered on days 1 and 8 over 90 minutes, and paclitaxel was administered on day 8 over 3 hours after 90 minutes from the end of the irinotecan infusion"><entity charOffset="1-11" id="DDI-PubMed.17409861.s4.e0" text="Irinotecan" /><entity charOffset="66-76" id="DDI-PubMed.17409861.s4.e1" text="paclitaxel" /><entity charOffset="153-163" id="DDI-PubMed.17409861.s4.e2" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.17409861.s4.e0" e2="DDI-PubMed.17409861.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17409861.s4.e0" e2="DDI-PubMed.17409861.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17409861.s4.e0" e2="DDI-PubMed.17409861.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17409861.s4.e1" e2="DDI-PubMed.17409861.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17409861.s4.e1" e2="DDI-PubMed.17409861.s4.e2" /></sentence><sentence text=" Irinotecan and paclitaxel were dose-escalated from 40 and 135 mg/m and repeated every 4 weeks"><entity charOffset="1-11" id="DDI-PubMed.17409861.s5.e0" text="Irinotecan" /><entity charOffset="16-26" id="DDI-PubMed.17409861.s5.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.17409861.s5.e0" e2="DDI-PubMed.17409861.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17409861.s5.e0" e2="DDI-PubMed.17409861.s5.e1" /></sentence><sentence text=" The authors also administered a higher dosage with preventive granulocyte colony-stimulating factor support from day 9" /><sentence text=" Thirty-one patients were assessed for toxicities and responses" /><sentence text=" Dose-limiting toxicities were neutropenia and febrile neutropenia" /><sentence text=" The dose of irinotecan 60 mg/m and paclitaxel 200 mg/m with preventive granulocyte colony-stimulating factor support was tolerable and suitable for a phase II trial"><entity charOffset="13-23" id="DDI-PubMed.17409861.s9.e0" text="irinotecan" /><entity charOffset="36-46" id="DDI-PubMed.17409861.s9.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.17409861.s9.e0" e2="DDI-PubMed.17409861.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17409861.s9.e0" e2="DDI-PubMed.17409861.s9.e1" /></sentence><sentence text=" Nine of 25 (36%) patients with non-small cell and all six patients with small cell carcinoma achieved partial response" /><sentence text=" The areas under the concentration versus time curves of irinotecan and its metabolites on day 8 were significantly higher than on day 1"><entity charOffset="57-67" id="DDI-PubMed.17409861.s11.e0" text="irinotecan" /></sentence><sentence text=" This combination therapy must be planned only after careful consideration of the drug-drug interaction" /><sentence text="" /></document>